View:
Download DOC
Download PDF
Download XLS
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Miller Derek
(Last) (First) (Middle)
ONE AMGEN CENTER DRIVE
(Street)
THOUSAND OAKS CA 91320
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/14/2022 		3. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Human Resources
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 5,843(1)(2) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Nqso (Right to Buy) 05/03/2018(3) 05/03/2026 Common Stock 1,524 156.35 D
Nqso (Right to Buy) 05/01/2019(4) 05/02/2027 Common Stock 2,069 162.6 D
Nqso (Right to Buy) 04/27/2020(5) 04/27/2028 Common Stock 1,821 177.46 D
Nqso (Right to Buy) 05/03/2021(6) 05/03/2029 Common Stock 3,692 177.31 D
Nqso (Right to Buy) 05/05/2022(7) 05/05/2030 Common Stock 3,365 236.36 D
Nqso (Right to Buy) 04/30/2023(8) 04/30/2031 Common Stock 3,405 239.64 D
Explanation of Responses:
1. These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Equity Incentive Plan: 81 RSUs which will vest on 4/27/2022; 614 RSUs which will vest on 4/27/2022; 283 RSUs which vest in installments of 139 on 5/3/2022 and 144 on 5/3/2023; 401 RSUs which vest in two installments of 132 on 5/5/2022 and 5/5/2023 and one installment of 137 on 5/5/2024; 392 RSUs which vest in two installments of 129 on 4/30/2023 and on 4/30/2024 and 134 on 4/30/2025; and 350 RSUs which vest in two installments of 175 on 11/5/2022 and 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2. These shares include 157 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3. 1,524 of these non-qualified stock options have vested and are exercisable.
4. 2,069 of these non-qualified stock options have vested and are exercisable.
5. 1,201 of these non-qualified stock options have vested and are exercisable and 620 of these options will vest and become exercisable on 4/27/2022.
6. 1,218 of these non-qualified stock options have vested and are exercisable and the remaining options will vest and become exercisable in installments of 1,218 on 5/3/2022 and 1,256 on 5/3/2023.
7. These non-qualified stock options will vest and become exercisable in two installments of 1,110 on 5/5/2022 and 5/5/2023 and one installment of 1,145 on 5/5/2024.
8. These non-qualified stock options will vest and become exercisable in three installments of 1,123 on 4/30/2023, 1,124 on 4/30/2024 and 1,158 on 4/30/2025.
/s/ Derek Miller 03/17/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Exhibit 24

Power of Attorney


		Know all men by these presents, that the undersigned hereby
constitutes and appoints each of Dennis Yai and Andrea A. Robinson,
signing singly, the undersigned's true and lawful attorney-in-fact to
execute for and on behalf of the undersigned Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended, and the rules thereunder, as may be required as a result
of the undersigneds position as an officer and/or director of Amgen Inc.
(the "Company").

		The undersigned hereby grants to each such attorney-in-fact
full power and authority to execute such Forms 3, 4 and 5 as fully to all
intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying
and confirming all that such attorney-in-fact, or such attorney-in-fact's
substitute or substitutes, shall lawfully do or cause to be done by virtue
of this power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigned's
responsibilities to comply with Section 16 of the Securities Exchange Act
of 1934, as amended.

		This Power of Attorney shall remain in full force and
effect until the undersigned is no longer required to file Forms 3, 4
and 5 with respect to the undersigneds holdings of and transactions
in securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.

		IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of this 3rd day of March, 2022.




						/s/   Derek Miller
						Name: Derek Miller